N/A N=269 Complete Histologic Resection of Adenomatous Polyps?
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=204 Adjuvant HIPEC in High Risk Colon Cancer
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
N/A N=386 Efficacy of Segmental Examination Twice of the Proximal Colon on Adenoma Detection
Colonic Polyps
Primary: Difference of Adenoma Detection Rate in the Proximal Colon Among 2 Group. — 0.236; 0.331 proportion of participants
Phase 2 N=45 Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
Adenomatous Polyp · Recurrent Colon Cancer · Recurrent Rectal Cancer
Primary: Change in ACF pERK Levels
N/A N=35 Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma
Colorectal Adenoma · Risk Reduction
Primary: Change in Beta Catenin Expression — 100; 100; 100; 100 percentage of positive cells
Phase 2 N=46 Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Risk for Colorectal Cancer
Primary: Number of Participants With Anti Muc-1 Antibody — 39 participants
Phase 2 N=64 Neoadjuvant Therapy for Locally Advanced Colon Cancer
Colon Cancer · Neoadjuvant Therapy
Primary: Tumor Regression Rate of MSS/pMMR Patients — 7 Participants
Phase 4 N=480 Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT)
Colorectal Neoplasms
Primary: Number of Participants With Detected Proximal Diminutive (<10 mm) Adenoma Detection Rate — 86; 89; 83; 38 participants
N/A N=740 I-scan for Adenoma Detection
Colorectal Adenomatous Polyps
Primary: Number of Participants With Conventional Adenoma and Sessile Serrated Adenoma/Polyp Detected — 208; 171 Participants
Phase 2 N=20 Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
Cancer of Rectum · Cancer of the Rectum · Neoplasm, Rectum
Primary: Complete Response Rate — 12 Participants
N/A N=126 Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments
Colon Cancer Screening · Colon Polyps · Colon Adenomas
Primary: Adenoma Detection Rate — 52.4; 40.5; 54.8 percentage of adenomas detected
Phase 2 N=24 Phase II Study of Irinotecan and Panitumumab
Esophageal Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Phase 2 N=45 Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI
Adenomatous Polyp · Colorectal Cancer · Obesity
Primary: Change in Activated S6serine235 (i.e., the Ratio of pS6serine235/S6serine235) — 0.0228 weighted ratio of staining cells — p=> 0.773
N/A N=14,263 Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study
Colorectal Cancer · Advanced Adenocarcinoma · Serrated Polyp
Primary: ColoSense Sensitivity for Colorectal Cancer (CRC) — 25; 2 Participants
Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
N/A N=176 Adenoma Miss Rate With Water Exchange vs Carbon Dioxide Colonoscopy
Colonic Adenoma · Water Exchange Colonoscopy
Primary: Percentage of Overall Detected Adenomas Missed During the First Right-Colon Colonoscopy — 33.8; 17.5 percentage of detected adenomas
N/A N=1,262 A 4-arm Clinical Trial of Fuse®, EndoCuff™, EndoRings™ and Standard Colonoscopy
Colorectal Neoplasms
Primary: Adenomas Per Colonoscopy — 1.53; 1.82; 1.55; 1.30 Adenomas per Colonoscopy
N/A N=427 Use of a Distal Colonoscope Attachment to Increase Detection of Sessile Serrated Adenomas
Sessile Serrated Adenoma
Primary: Sessile Serrated Adenomas — 42; 59 colonoscopies
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
N/A N=739 CADDIE Trial - Computer Aided Diagnosis and Detection for Intelligent Endoscopy
Polyps · Adenoma Colon · Colorectal Polyp
Primary: To Evaluate Whether Using the CADDIE System Improves Endoscopist Detection of Adenomas During Colonoscopy. — 33.30; 25.20 ADR (% of participants)
N/A N=44 Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis
Primary: Number of Polyps — 18.6; 22.6 Number of Polyps
Phase 2 N=46 Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Attenuated Familial Adenomatous Polyposis · Familial Adenomatous Polyposis
Primary: Mean Percent Change in Duodenal Polyp Burden — -29.6 percent change in Duodenal Polyp Burden
N/A N=20 Patient-Derived Organoids for Rectal Cancer
Rectum Cancer
Primary: Number of Participants With Biopsies That Form Spherical Organoids — 14 Participants
Phase 2 N=40 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
Colorectal Adenoma · Colorectal Carcinoma
Primary: Number of Subjects Witha Change (IMPROVEMENT) in Colo-rectal Adenocarcinoma as Measured by Cyclooxygenase-2 Activity After 7 Days of Celecoxib — 2.0; 2.0 Participant
Phase 3 N=3,397 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Adenocarcinoma of the Colon · Stage III Colon Cancer
Primary: Disease-free Survival (Arms A and D: Wild-type KRAS Patients) — 74.6; 71.5 percentage of participants
Phase 2 N=34 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
Colorectal Cancer · Cancer of Gastrointestinal Tract
Primary: Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA) — 0; 0; 0; 2 Participants
Phase 2 N=38 Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Number of Participants Alive With and Without Disease Progression — 4; 6; 28 Participants
N/A N=130 Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Esophageal Carcinoma
Primary: Overall Survival — 12; 11; 13 participants
Phase 2 N=13 Genistein in Treatment of Metastatic Colorectal Cancer
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
Phase 2 N=47 RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
Colorectal Cancer
Primary: Progression Free Survival at Six Months — 87 percentage of participants